Azza SARFRAZ, Hamna MALIK, Hira BINT ABDUL JABBAR, Farah LATIF, Muzna SARFRAZ, Zouina SARFRAZ

The efficacy of anakinra compared to standard care of treatment for COVID-19: a metaanalysis

Background/aim: As SARS-CoV-2 continues to spread worldwide, this study brings to light the link that anakinra, a recombinant IL-1 receptor antagonist, has in averting grave clinical outcomes. The objectives of this meta-analysis are to investigate the effects of anakinra in interventional groups compared to control/standard of care groups on mortality along with the provision of a prevalence estimate of the variables associated with death (C-reactive protein-CRP, ferritin, acute respiratory distress syndrome-ARDS). Materials and methods: According to the PRISMA 2020 statement guidelines, a systematic search was conducted from December 19, 2020, until December 10, 2021, with keywords including COVID-19, coronavirus, SARS-CoV-2, anakinra, mortality, across the following databases: PubMed/MEDLINE, Scopus, Web of Science, CINAHL Plus, and Cochrane. A random-effects model was applied using RevMan 5.4 for all statistical analyses. Results: The meta-analysis pooled in 1297 participants with 565 (43.6%) patients in the anakinra group. When comparing to the control/standard of care group, the anakinra group had a much lower risk of death (RR = 0.47. 95% CI = 0.37–0.59, Z = 6.44; P < 0.001). In addition to the risk of death being reduced by around 50% in the interventional group, prognostic indicators such as CRP and ferritin were improved with fewer occurrences of severe ARDS. Conclusion: Patients with COVID-19 pneumonia may be treated with anakinra as a safe and viable treatment modality to defer adverse outcomes such as a death in the 28-day period. Despite an auspicious premise, our findings must be used with caution as adequately powered randomized, placebo-controlled trials are required to corroborate these findings.

PDF

___

1. Doskaliuk B, Yatsyshyn R, Klishch I, Zimba O. COVID-19 from a rheumatology perspective: bibliometric and altmetric analysis. Rheumatology International 2021; 41 (12): 2091- 2103. doi: 10.1007/s00296-021-04987-0.
2. Kyriazopoulou E, Huet T, Cavalli G, Gori A, Kyprianou M, et al. Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. Lancet Rheumatology 2021; 3 (10): 690-697. doi: 10.1016/S2665- 9913(21)00216-2.
3. Schulert GS, Grom AA. Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies. Annual Review of Medicine 2015; 66 :145-59. doi: 10.1146/ annurev-med-061813-012806.
4. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet 2020; 395 (10229): 1033- 1034. doi: 10.1016/S0140-6736(20)30628-0.
5. Kooistra EJ, Waalders NJB, Grondman I, Janssen NAF, de Nooijer AH, et al. Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study. Critical Care 2020; 24 (1): 688. doi: 10.1186/s13054-020-03364-w.
6. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PLoS Medicine 2021; 18 (3): e1003583. doi: 10.1371/journal.pmed.1003583.
7. Sarfraz A, Sarfraz Z, Sanchez-Gonzalez M, Michel J, Michel G, et al. Randomized controlled trials of remdesivir in hospitalized coronavirus disease 2019 patients: a meta-analysis. Turkish Journal of Emergency Medicine 2021; 21 (2): 43-50. doi: 10.4103/2452-2473.309139.
8. Cauchois R, Koubi M, Delarbre D, Manet C, Carvelli J, et al. Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19. Proceedings of the National Academy of Sciences of the United States of America 2020; 117 (32): 18951-18953. doi: 10.1073/pnas.2009017117.
9. Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G, et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatology 2020; 2 (7): e393-e400. doi: 10.1016/ S2665-9913(20)30164-8.
10. Cavalli G, Larcher A, Tomelleri A, Campochiaro C, Della-Torre E, et al. Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. Lancet Rheumatology 2021; 3 (4): 253-261. doi: 10.1016/S2665-9913(21)00012-6.
11. Bozzi G, Mangioni D, Minoia F, Aliberti S, Grasselli G, et al. Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study. Journal of Allergy and Clinical Immunology 2021; 147 (2): 561-566.e4. doi: 10.1016/j. jaci.2020.11.006.
12. Kooistra EJ, Waalders NJB, Grondman I, Janssen NAF, de Nooijer AH, et al. Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study. Critical Care 2020; 24 (1): 688. doi: 10.1186/s13054-020-03364-w.
13. Balkhair A, Al-Zakwani I, Al Busaidi M, Al-Khirbash A, Al Mubaihsi S, et al. Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study. International Journal of Infectious Diseases 2021; 103: 288-296. doi: 10.1016/j.ijid.2020.11.149.
14. CORIMUNO-19 Collaborative group. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-tomoderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. The Lancet Respiratory Medicine 2021; 9 (3): 295-304. doi: 10.1016/S2213-2600(20)30556-7.
15. Kyriazopoulou E, Panagopoulos P, Metallidis S, Dalekos GN, Poulakou G, et al. An open label trial of anakinra to prevent respiratory failure in COVID-19. Elife 2021; 10: e66125. doi: 10.7554/eLife.66125.
16. Pontali E, Volpi S, Signori A, Antonucci G, Castellaneta M, et al. Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia. The Journal of Allergy and Clinical Immunology 2021; 147 (4): 1217-1225. doi: 10.1016/j.jaci.2021.01.024.
17. Franzetti M, Forastieri A, Borsa N, Pandolfo A, Molteni C, et al. IL-1 Receptor antagonist anakinra in the treatment of COVID-19 acute respiratory distress syndrome: a retrospective, observational study. Journal of Immunology 2021; 206 (7): 1569-1575. doi: 10.4049/jimmunol.2001126.
18. Sarfraz A, Sarfraz Z, Barrios A, Agadi K, Thevuthasan S, et al. Understanding and promoting racial diversity in healthcare settings to address disparities in pandemic crisis management. Journal of Primary Care and Community Health 2021;12: 21501327211018354. doi: 10.1177/21501327211018354.